Applications and limitations of oncogene mutation testing in clinical cytopathology

Seminars in Diagnostic Pathology

Volumn 30, Issue 4, 2013, Pages 284-297

  Bellevicine, Claudio ^a   Vita, Giulia De ^b   Malapelle, Umberto ^a   Troncone, Giancarlo ^a,c  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^b REFERRAL CANCER CENTER OF BASILICATA   (Italy)

^c CEINGE BIOTECNOLOGIE AVANZATE   (Italy)

Author keywords

Aspiration; BRAF; C KIT; Cytology; EGFR; KRAS; NRAS; PCR

Indexed keywords

DNA;

ARTICLE; CYTOPATHOLOGY; DIAGNOSTIC TEST; DISEASE MARKER; DNA DETERMINATION; DNA SEQUENCE; GENE MUTATION; HISTOLOGY; HUMAN; IN VITRO STUDY; MUTATIONAL ANALYSIS; ONCOGENE; ONCOGENE MUTATION TESTING; PERFORMANCE; PRIORITY JOURNAL; STROMA CELL; TISSUE FIXATION; TISSUE SECTION; TUMOR CELL; VALIDATION PROCESS;

ASPIRATION; BRAF; C-KIT; CYTOLOGY; EGFR; KRAS; NRAS; PCR;

CYTODIAGNOSIS; DNA MUTATIONAL ANALYSIS; HUMANS; MUTATION; NEOPLASMS; ONCOGENES; SPECIMEN HANDLING;

EID: 84890203026     PISSN: 07402570     EISSN: 19301111     Source Type: Journal    
DOI: 10.1053/j.semdp.2013.11.008     Document Type: Article

References (107)

1. Rimm D.L. Molecular biology in cytopathology: current applications and future directions. Cancer 2000, 90(1):1-9.
2. Clark D.P. Seize the opportunity: underutilization of fine-needle aspiration biopsy to inform targeted cancer therapy decisions. Cancer Cytopathol 2009, 117(5):289-297.
3. Sequist L.V., Bell D.W., Lynch T.J., Haber D.A. Molecular predictors of response to epidermal growth factor receptor antagonists in non-small-cell lung cancer. J Clin Oncol 2007, 25(5):587-595.
4. Malapelle U., Bellevicine C., Zeppa P., Palombini L., Troncone G. Cytology-based gene mutation tests to predict response to anti-epidermal growth factor receptor therapy: a review. Diagn Cytopathol 2011, 39(9):703-710.
5. Centeno B.A., Enkemann S.A., Coppola D., Huntsman S., Bloom G., Yeatman T.J. Classification of human tumors using gene expression profiles obtained after microarray analysis of fine-needle aspiration biopsy samples. Cancer 2005, 105(2):101-109.
6. Symmans W.F., Ayers M., Clark E.A., et al. Total RNA yield and microarray gene expression profiles from fine-needle aspiration biopsy and core-needle biopsy samples of breast carcinoma. Cancer 2003, 97(12):2960-2971.
7. Aisner D.L., Deshpande C., Baloch Z., et al. Evaluation of EGFR mutation status in cytology specimens: an institutional experience. Diagn Cytopathol 2011, 18(4):316-323.
8. Troncone G., Cozzolino I., Fedele M., Malapelle U., Palombini L. Preparation of thyroid FNA material for routine cytology and BRAF testing: a validation study. Diagn Cytopathol 2010, 38(3):172-176.
9. Lee Y.S., Jin G.Y., Han Y.M., Chung M.J., Park H.S. Computed tomography-guided transthoracic needle aspiration biopsy of intrapulmonary lesions: utility of a liquid-based cytopreparatory technique. Acta Cytol 2008, 52(6):665-670.
10. Zatelli M.C., Trasforini G., Leoni S., et al. BRAF V600E mutation analysis increases diagnostic accuracy for papillary thyroid carcinoma in fine-needle aspiration biopsies. Eur J Endocrinol 2009, 161(3):467-473.
11. Schmitt F.C. Molecular cytopathology and flow cytometry: pre-analytical procedures matter. Cytopathology 2011, 22(6):355-357.
12. Castle P.E., Hildesheim A., Schiffman M., et al. Stability of archived liquid-based cytologic specimens. Cancer 2003, 99(5):320-322.
13. Cohen M.B., Egerter D.P., Holly E.A., Ahn D.K., Miller T.R. Pancreatic adenocarcinoma: regression analysis to identify improved cytologic criteria. Diagn Cytopathol 1991, 7(4):341-345.
14. Salvatore G., Giannini R., Faviana P., et al. Analysis of BRAF point mutation and RET/PTC rearrangement refines the fine-needle aspiration diagnosis of papillary thyroid carcinoma. J Clin Endocrinol Metab 2004, 89(10):5175-5180.
15. Rowe L.R., Bentz B.G., Bentz J.S. Utility of BRAF V600E mutation detection in cytologically indeterminate thyroid nodules. Cytojournal 2006, 3:10.
16. Kim S.K., Kim D.L., Han H.S., et al. Pyrosequencing analysis for detection of a BRAFV600E mutation in an FNAB specimen of thyroid nodules. Diagn Mol Pathol 2008, 17(2):118-125.
17. Chowdhuri S.R., Xi L., Pham T.H., et al. EGFR and KRAS mutation analysis in cytologic samples of lung adenocarcinoma enabled by laser capture microdissection. Mod Pathol 2012, 25(4):548-555.
18. Betz B.L., Roh M.H., Weigelin H.C., et al. The application of molecular diagnostic studies interrogating EGFR and KRAS mutations to stained cytologic smears of lung carcinoma. Am J Clin Pathol 2011, 136(4):564-571.
19. Savic S., Tapia C., Grilli B., et al. Comprehensive epidermal growth factor receptor gene analysis from cytological specimens of non-small-cell lung cancers. Br J Cancer 2008, 98(1):154-160.
20. Boldrini L., Gisfredi S., Ursino S., et al. Mutational analysis in cytological specimens of advanced lung adenocarcinoma: a sensitive method for molecular diagnosis. J Thorac Oncol 2007, 2(12):1086-1090.
21. Molina-Vila M.A., Bertran-Alamillo J., Reguart N., et al. A sensitive method for detecting EGFR mutations in non-small cell lung cancer samples with few tumor cells. J Thorac Oncol 2008, 3(11):1224-1235.
22. Billah S., Stewart J., Staerkel G., Chen S., Gong Y., Guo M. EGFR and KRAS mutations in lung carcinoma: molecular testing by using cytology specimens. Cancer Cytopathol 2011, 119(2):111-117.
23. Smouse J.H., Cibas E.S., Janne P.A., Joshi V.A., Zou K.H., Lindeman N.I. EGFR mutations are detected comparably in cytologic and surgical pathology specimens of nonsmall cell lung cancer. Cancer Cytopathol 2009, 117(1):67-72.
24. Sanz-Santos J., Serra P., Andreo F., Llatjos M., Castella E., Monso E. Contribution of cell blocks obtained through endobronchial ultrasound-guided transbronchial needle aspiration to the diagnosis of lung cancer. BMC Cancer 2012, 12:34. [Published online 21 January 2012].
25. Han H.S., Lim S.N., An J.Y., et al. Detection of EGFR mutation status in lung adenocarcinoma specimens with different proportions of tumor cells using two methods of differential sensitivity. J Thorac Oncol 2012, 7(2):355-364.
26. Hookim K., Roh M.H., Willman J., et al. Application of immunocytochemistry and BRAF mutational analysis to direct smears of metastatic melanoma. Cancer Cytopathol 2012, 120(1):52-61.
27. van Eijk R., Licht J., Schrumpf M., et al. Rapid KRAS, EGFR, BRAF and PIK3CA mutation analysis of fine needle aspirates from non-small-cell lung cancer using allele-specific qPCR. PLoS One 2011, 6(3):e17791.
28. Killian J.K., Walker R.L., Suuriniemi M., et al. Archival fine-needle aspiration cytopathology (FNAC) samples: untapped resource for clinical molecular profiling. J Mol Diagn 2010, 12(6):739-745.
29. Guerriero E., Ferraro A., Desiderio D., et al. UbcH10 expression on thyroid fine-needle aspirates. Cancer Cytopathol 2010, 118(3):157-165.
30. Sanchez N., Selvaggi S.M. Utility of cell blocks in the diagnosis of thyroid aspirates. Diagn Cytopathol 2006, 34(2):89-92.
31. Natu S., Hoffman J., Siddiqui M., Hobday C., Shrimankar J., Harrison R. The role of endobronchial ultrasound guided transbronchial needle aspiration cytology in the investigation of mediastinal lymphadenopathy and masses, the North Tees experience. J Clin Pathol 2010, 63(5):445-451.
32. Castle P.E., Wheeler C.M., Solomon D., Schiffman M., Peyton C.L. Interlaboratory reliability of hybrid capture 2. Am J Clin Pathol 2004, 122(2):238-245.
33. Pang N.K., Chin S.Y., Nga M.E., et al. Comparative validation of c-kit exon 11 mutation analysis on cytology samples and corresponding surgical resections of gastrointestinal stromal tumours. Cytopathology 2009, 20(5):297-303.
34. Malapelle U., de Rosa N., Rocco D., et al. EGFR and KRAS mutations detection on lung cancer liquid-based cytology: a pilot study. J Clin Pathol 2012, 65(1):87-91.
35. Malapelle U., de Rosa N., Bellevicine C., et al. EGFR mutations detection on liquid-based cytology: is microscopy still necessary?. J Clin Pathol 2012, 65(6):561-564.
36. Sapio M.R., Posca D., Raggioli A., et al. Detection of RET/PTC, TRK and BRAF mutations in preoperative diagnosis of thyroid nodules with indeterminate cytological findings. Clin Endocrinol (Oxf) 2007, 66(5):678-683.
37. Troncone G., Malapelle U., Cozzolino I., Palombini L. KRAS mutation analysis on cytological specimens of metastatic colo-rectal cancer. Diagn Cytopathol 2010, 38(12):869-873.
38. Sapio M.R., Guerra A., Posca D., et al. Combined analysis of galectin-3 and BRAFV600E improves the accuracy of fine-needle aspiration biopsy with cytological findings suspicious for papillary thyroid carcinoma. Endocr Relat Cancer 2007, 14(4):1089-1097.
39. Moses W., Weng J., Sansano I., et al. Molecular testing for somatic mutations improves the accuracy of thyroid fine-needle aspiration biopsy. World J Surg 2010, 34(11):2589-2594.
40. Nam S.Y., Han B.K., Ko E.Y., et al. BRAF V600E mutation analysis of thyroid nodules needle aspirates in relation to their ultrasongraphic classification: a potential guide for selection of samples for molecular analysis. Thyroid 2010, 20(3):273-279.
41. Musholt T.J., Fottner C., Weber M.M., et al. Detection of papillary thyroid carcinoma by analysis of BRAF and RET/PTC1 mutations in fine-needle aspiration biopsies of thyroid nodules. World J Surg 2010, 34(11):2595-2603.
42. Canadas-Garre M., Becerra-Massare P., Lopez de la Torre-Casares M., et al. Reduction of false-negative papillary thyroid carcinomas by the routine analysis of BRAF(T1799A) mutation on fine-needle aspiration biopsy specimens: a prospective study of 814 thyroid FNAB patients. Ann Surg 2012, 255(5):986-992.
43. Nakajima T., Yasufuku K., Suzuki M., et al. Assessment of epidermal growth factor receptor mutation by endobronchial ultrasound-guided transbronchial needle aspiration. Chest 2007, 132(2):597-602.
44. Horiike A., Kimura H., Nishio K., et al. Detection of epidermal growth factor receptor mutation in transbronchial needle aspirates of non-small cell lung cancer. Chest 2007, 131(6):1628-1634.
45. Shih J.Y., Gow C.H., Yu C.J., et al. Epidermal growth factor receptor mutations in needle biopsy/aspiration samples predict response to gefitinib therapy and survival of patients with advanced nonsmall cell lung cancer. Int J Cancer 2006, 118(4):963-969.
46. Smith G.D., Chadwick B.E., Willmore-Payne C., Bentz J.S. Detection of epidermal growth factor receptor gene mutations in cytology specimens from patients with non-small cell lung cancer utilising high-resolution melting amplicon analysis. J Clin Pathol 2008, 61(4):487-493.
47. Lozano M.D., Zulueta J.J., Echeveste J.I., et al. Assessment of epidermal growth factor receptor and K-ras mutation status in cytological stained smears of non-small cell lung cancer patients: correlation with clinical outcomes. Oncologist 2011, 16(6):877-885.
48. Nomoto K., Tsuta K., Takano T., et al. Detection of EGFR mutations in archived cytologic specimens of non-small cell lung cancer using high-resolution melting analysis. Am J Clin Pathol 2006, 126(4):608-615.
49. van Krieken J.H., Jung A., Kirchner T., et al. KRAS mutation testing for predicting response to anti-EGFR therapy for colorectal carcinoma: proposal for an European quality assurance program. Virchows Arch 2008, 453(5):417-431.
50. Cross J. DxS Ltd. Pharmacogenomics 2008, 9(4):463-467.
51. Malapelle U., Bellevicine C., Russo A., Salatiello M., Palombini L., Troncone G. KRAS testing on colo-rectal carcinoma cytological imprints. Diagn Cytopathol 2011, 39(4):274-277.
52. Nicholson A.G., Gonzalez D., Shah P., et al. Refining the diagnosis and EGFR status of non-small cell lung carcinoma in biopsy and cytologic material, using a panel of mucin staining, TTF-1, cytokeratin 5/6, and P63, and EGFR mutation analysis. J Thorac Oncol 2010, 5(4):436-441.
53. Tanaka T., Nagai Y., Miyazawa H., et al. Reliability of the peptide nucleic acid-locked nucleic acid polymerase chain reaction clamp-based test for epidermal growth factor receptor mutations integrated into the clinical practice for non-small cell lung cancers. Cancer Sci 2007, 98(2):246-252.
54. Di Lorito A., Schmitt F.C. (Cyto)pathology and sequencing: next (or last) generation?. Diagn Cytopathol 2011, 40(5):459-461.
55. Cibas E.S., Ali S.Z. The Bethesda system for reporting thyroid cytopathology. Am J Clin Pathol 2009, 132(5):658-665.
56. Clark D.P. Molecular diagnostics on thyroid fine-needle aspirations: the pathway to value creation. Cancer Cytopathol 2010, 118(1):14-16.
57. Xing M. BRAF mutation in papillary thyroid cancer: pathogenic role, molecular bases, and clinical implications. Endocr Rev 2007, 28(7):742-762.
58. Sapio M.R., Posca D., Troncone G., et al. Detection of BRAF mutation in thyroid papillary carcinomas by mutant allele-specific PCR amplification (MASA). Eur J Endocrinol 2006, 154(2):341-348.
59. Deveci M.S., Deveci G., LiVolsi V.A., Baloch Z.W. Fine-needle aspiration of follicular lesions of the thyroid. Diagnosis and follow-up. Cytojournal 2006, 3:9.
60. Monzon F.A., Ogino S., Hammond M.E., Halling K.C., Bloom K.J., Nikiforova M.N. The role of KRAS mutation testing in the management of patients with metastatic colorectal cancer. Arch Pathol Lab Med 2009, 133(10):1600-1606.
61. Yip L., Nikiforova M.N., Carty S.E., et al. Optimizing surgical treatment of papillary thyroid carcinoma associated with BRAF mutation. Surgery 2009, 146(6):1215-1223.
62. Nikiforov Y.E., Steward D.L., Robinson-Smith T.M., et al. Molecular testing for mutations in improving the fine-needle aspiration diagnosis of thyroid nodules. J Clin Endocrinol Metab 2009, 94(6):2092-2098.
63. Bartolazzi A., Gasbarri A., Papotti M., et al. Application of an immunodiagnostic method for improving preoperative diagnosis of nodular thyroid lesions. Lancet 2001, 357(9269):1644-1650.
64. Bartolazzi A., Orlandi F., Saggiorato E., et al. Galectin-3-expression analysis in the surgical selection of follicular thyroid nodules with indeterminate fine-needle aspiration cytology: a prospective multicentre study. Lancet Oncol 2008, 9(6):543-549.
65. Gasbarri A., Marchetti C., Iervasi G., et al. From the bench to the bedside. Galectin-3 immunodetection for improving the preoperative diagnosis of the follicular thyroid nodules. Biomed Pharmacother 2004, 58(6-7):356-359.
66. Mehrotra P., Okpokam A., Bouhaidar R., et al. Galectin-3 does not reliably distinguish benign from malignant thyroid neoplasms. Histopathology 2004, 45(5):493-500.
67. Trovisco V., Soares P., Sobrinho-Simoes M. B-RAF mutations in the etiopathogenesis, diagnosis, and prognosis of thyroid carcinomas. Hum Pathol 2006, 37(7):781-786.
68. Eltoum I.A., Alston E.A., Roberson J. Trends in pancreatic pathology practice before and after implementation of endoscopic ultrasound-guided fine-needle aspiration: an example of disruptive innovation effect?. Arch Pathol Lab Med 2012, 136(4):447-453.
69. Do H., Krypuy M., Mitchell P.L., Fox S.B., Dobrovic A. High resolution melting analysis for rapid and sensitive EGFR and KRAS mutation detection in formalin fixed paraffin embedded biopsies. BMC Cancer 2008, 8:142. [Published online 21 May 2008].
70. Mitsudomi T., Kosaka T., Endoh H., et al. Mutations of the epidermal growth factor receptor gene predict prolonged survival after gefitinib treatment in patients with non-small-cell lung cancer with postoperative recurrence. J Clin Oncol 2005, 23(11):2513-2520.
71. Stelow E.B., Bardales R.H., Lai R., et al. The cytological spectrum of chronic pancreatitis. Diagn Cytopathol 2005, 32(2):65-69.
72. Hruban R.H., Wilentz R.E., Kern S.E. Genetic progression in the pancreatic ducts. Am J Pathol 2000, 156(6):1821-1825.
73. Hruban R.H., van Mansfeld A.D., Offerhaus G.J., et al. K-ras oncogene activation in adenocarcinoma of the human pancreas. A study of 82 carcinomas using a combination of mutant-enriched polymerase chain reaction analysis and allele-specific oligonucleotide hybridization. Am J Pathol 1993, 143(2):545-554.
74. Nakamura Y., Onda M., Uchida E. Analysis of K-ras codon 12 point mutations using duodenal lavage fluid for diagnosis of pancreatic carcinoma. Pancreas 1999, 18(2):133-140.
75. Iwao T., Hanada K., Tsuchida A., Hirata M., Eguchi N., Kajiyama G. The establishment of a preoperative diagnosis of pancreatic carcinoma using cell specimens from pancreatic duct brushing with special attention to p53 mutations. Cancer 1998, 82(8):1487-1494.
76. Tada M., Komatsu Y., Kawabe T., et al. Quantitative analysis of K-ras gene mutation in pancreatic tissue obtained by endoscopic ultrasonography-guided fine needle aspiration: clinical utility for diagnosis of pancreatic tumor. Am J Gastroenterol 2002, 97(9):2263-2270.
77. Reicher S., Boyar F.Z., Albitar M., et al. Fluorescence in situ hybridization and K-ras analyses improve diagnostic yield of endoscopic ultrasound-guided fine-needle aspiration of solid pancreatic masses. Pancreas 2011, 40(7):1057-1062.
78. Luttges J., Schlehe B., Menke M.A., Vogel I., Henne-Bruns D., Kloppel G. The K-ras mutation pattern in pancreatic ductal adenocarcinoma usually is identical to that in associated normal, hyperplastic, and metaplastic ductal epithelium. Cancer 1999, 85(8):1703-1710.
79. Luttges J., Reinecke-Luthge A., Mollmann B., et al. Duct changes and K-ras mutations in the disease-free pancreas: analysis of type, age relation and spatial distribution. Virchows Arch 1999, 435(5):461-468.
80. Luttges J., Diederichs A., Menke M.A., Vogel I., Kremer B., Kloppel G. Ductal lesions in patients with chronic pancreatitis show K-ras mutations in a frequency similar to that in the normal pancreas and lack nuclear immunoreactivity for p53. Cancer 2000, 88(11):2495-2504.
81. Sturm P.D., Hruban R.H., Ramsoekh T.B., et al. The potential diagnostic use of K-ras codon 12 and p53 alterations in brush cytology from the pancreatic head region. J Pathol 1998, 186(3):247-253.
82. van Heek T., Rader A.E., Offerhaus G.J., et al. p53, and DPC4 (MAD4) alterations in fine-needle aspirates of the pancreas: a molecular panel correlates with and supplements cytologic diagnosis. Am J Clin Pathol 2002, 117(5):755-765.
83. Sepe P.S., Moparty B., Pitman M.B., Saltzman J.R., Brugge W.R. EUS-guided FNA for the diagnosis of GI stromal cell tumors: sensitivity and cytologic yield. Gastrointest Endosc 2009, 70(2):254-261.
84. van der Waaij L.A., van Dullemen H.M., Porte R.J. Cyst fluid analysis in the differential diagnosis of pancreatic cystic lesions: a pooled analysis. Gastrointest Endosc 2005, 62(3):383-389.
85. Rosell R., Perez-Roca L., Sanchez J.J., et al. Customized treatment in non-small-cell lung cancer based on EGFR mutations and BRCA1 mRNA expression. PLoS One 2009, 4(5):e5133.
86. Izeradjene K., Combs C., Best M., et al. Kras(G12D) and Smad4/Dpc4 haploinsufficiency cooperate to induce mucinous cystic neoplasms and invasive adenocarcinoma of the pancreas. Cancer Cell 2007, 11(3):229-243.
87. Sawhney M.S., Devarajan S., O'Farrel P., et al. Comparison of carcinoembryonic antigen and molecular analysis in pancreatic cyst fluid. Gastrointest Endosc 2009, 69(6):1106-1110.
88. Khalid A., McGrath K.M., Zahid M., et al. The role of pancreatic cyst fluid molecular analysis in predicting cyst pathology. Clin Gastroenterol Hepatol 2005, 3(10):967-973.
89. Ciardiello F., Tortora G. EGFR antagonists in cancer treatment. N Engl J Med 2008, 358(11):1160-1174.
90. da Cunha Santos G., Saieg M.A., Geddie W., Leighl N. EGFR gene status in cytological samples of nonsmall cell lung carcinoma: controversies and opportunities. Cancer Cytopathol 2011, 119(2):80-91.
91. Travis W.D., Brambilla E., Noguchi M., et al. International association for the study of lung cancer/american thoracic society/european respiratory society international multidisciplinary classification of lung adenocarcinoma. J Thorac Oncol 2011, 6(2):244-285.
92. Pang N.K., Nga M.E., Chin S.Y., et al. KRAS and BRAF mutation analysis can be reliably performed on aspirated cytological specimens of metastatic colorectal carcinoma. Cytopathology 2011, 22(6):358-364.
93. Bouchahda M., Karaboue A., Saffroy R., et al. Acquired KRAS mutations during progression of colorectal cancer metastases: possible implications for therapy and prognosis. Cancer Chemother Pharmacol 2010, 66(3):605-609.
94. Cozzolino I., Malapelle U., Carlomagno C., Palombini L., Troncone G. Metastasis of colon cancer to the thyroid gland: a case diagnosed on fine-needle aspirate by a combined cytological, immunocytochemical, and molecular approach. Diagn Cytopathol 2010, 38(12):932-935.
95. Blay J.Y., von Mehren M., Blackstein M.E. Perspective on updated treatment guidelines for patients with gastrointestinal stromal tumors. Cancer 2010, 116(22):5126-5137.
96. Layfield L.J., Wallander M.L. Diagnosis of gastrointestinal stromal tumors from minute specimens: cytomorphology, immunohistochemistry, and molecular diagnostic findings. Diagn Cytopathol 2012, 40(6):484-490.
97. Medeiros F., Corless C.L., Duensing A., et al. KIT-negative gastrointestinal stromal tumors: proof of concept and therapeutic implications. Am J Surg Pathol 2004, 28(7):889-894.
98. Yamamoto H., Kojima A., Nagata S., Tomita Y., Takahashi S., Oda Y. KIT-negative gastrointestinal stromal tumor of the abdominal soft tissue: a clinicopathologic and genetic study of 10 cases. Am J Surg Pathol 2011, 35(9):1287-1295.
99. Hirota S., Isozaki K., Moriyama Y., et al. Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors. Science 1998, 279(5350):577-580.
100. Antonescu C.R. The GIST paradigm: lessons for other kinase-driven cancers. J Pathol 2011, 223(2):251-261.
101. Gomes A.L., Bardales R.H., Milanezi F., Reis R.M., Schmitt F. Molecular analysis of c-Kit and PDGFRA in GISTs diagnosed by EUS. Am J Clin Pathol 2007, 127(1):89-96.
102. Rosai J., Carcangiu M.L., DeLellis R.A., Simoes M.S. Recommendations for the reporting of thyroid carcinomas. Association of Directors of Anatomic and Surgical Pathology. Hum Pathol 2000, 31(10):1199-1201.
103. Eisenberg B.L., Trent J.C. Adjuvant and neoadjuvant imatinib therapy: current role in the management of gastrointestinal stromal tumors. Int J Cancer 2011, 129(11):2533-2542.
104. Blesius A., Cassier P.A., Bertucci F., et al. Neoadjuvant imatinib in patients with locally advanced non metastatic GIST in the prospective BFR14 trial. BMC Cancer 2011, 11:72. [Published online 15 February 2011].
105. Grossmann A.H., Grossmann K.F., Wallander M.L. Molecular testing in malignant melanoma. Diagn Cytopathol 2012, 40(6):503-510.
106. Lee S., Brophy V.H., Cao J., et al. Analytical performance of a PCR assay for the detection of KRAS mutations (codons 12/13 and 61) in formalin-fixed paraffin-embedded tissue samples of colorectal carcinoma. Virchows Arch 2011, 460(2):141-149.
107. Filho A.L., Schmitt F.C. Cytology education in the 21st century: living in the past or crossing the Rubicon?. Acta Cytol 2010, 54(4):654-656.